Project Grant R01CA295834
Award Date
3/17/25
Completion Date
2/28/30
Dollars Obligated
$567K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $2,203,647 Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to identify and advance small molecule drugs that target transcriptional fusion oncoproteins. The University of Texas Southwestern Medical Center is the prime awardee, leveraging expertise in small molecule drug discovery, target identification, and protein biochemistry to achieve two key objectives:
Target the transcriptional machinery...
This federal Project Grant award, valued at $267,527, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The University of Texas MD Anderson Cancer Center. The funding supports research aimed at overcoming resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors by targeting SMARCA2, a known synthetic lethal interaction partner to SMARCA4. Key planned activities include investigating the mechanism of resistance, developing...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports the University of Texas MD Anderson Cancer Center's research on how the transcription factor BHLHE40 regulates the anti-tumor immune response of CD4 and CD8 T cells during cancer immunotherapy. The $606,635 award will fund studies to determine the role of BHLHE40 in CD4 and CD8 T cell effector function, and how its regulation impacts the tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $590,625 to the University of California, Davis to develop a novel therapeutic strategy targeting mutant p53, a key driver of tumor progression, metastasis, and therapy resistance. The research aims to:
Determine how mutant p53 expression is regulated by the CDK4/6-RBM38-eIF4G axis and evaluate the role of mutant p53 as a target of CDK4/6 inhibitors for treating triple-negative...
This $401,087 Project Grant awarded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) supports research to investigate the mechanistic regulation of a tumor "persister" state induced by mTOR inhibition, and to test therapeutic strategies to target residual tumors in preclinical cancer models. The goal is to prevent tumor recurrence in patients. The award recipient, The Methodist Hospital Research Institute Division, will leverage advanced...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $610,783 in funding to The Methodist Hospital Research Institute to develop a novel gene therapy approach to modulate the tumor microenvironment and enhance antigen-specific anti-tumor immunity. The key products and services to be delivered include:
Use of a recombinant adenoviral vector with high tumor-specific expression of the herpes simplex virus-thymidine kinase (HSV-TK)...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.398 - Cancer Research Manpower) to the Sloan-Kettering Institute for Cancer Research in the amount of $154,642.00 on March 1, 2025. The grant supports research aimed at identifying novel, conserved cancer-specific antigens in metastatic colorectal cancer (mCRC) that could serve as targets for T cell-based immunotherapies.
Specifically, the research will systematically elucidate the evolving immunopeptidome, or repertoire of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to New York University School of Medicine to conduct research on pyrimidine metabolism and its impact on cancer cell function and anti-tumor immune response. The $544,658 award, effective June 1, 2024 through May 31, 2029, aims to: 1) investigate how pyrimidine overflow and disruption of the p53-dependent ribosome biogenesis checkpoint differentially affect cancer and...
This federal Project Grant award provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) supports research to investigate the interplay between the physical properties of the metastatic microenvironment and the ability of cytotoxic lymphocytes to effectively target and destroy cancer cells. The $577,034 award to the Sloan-Kettering Institute for Cancer Research, spanning 5 years from Aug 2024 to Jul 2029, will examine how microenvironmental stiffness...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) totaling $620,820 supports research to investigate mechanisms of immune therapy resistance. The key objectives are to:
Understand the molecular regulation and transcriptional mechanisms of the CREB5 transcription factor, which was identified as a driver of immune evasion in preliminary studies.
Characterize the CREB5-interacting proteins that mediate increased deposition of collagen...